JFA
KPTI icon

JNBA Financial Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

JNBA Financial Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-27
Closed -$2K – 651
2019
Q2 		$2K Buy
+27
New +$2.17K ﹤0.01% 603

Other funds holding KPTI

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JNBA Financial Advisors's KPTI Position: Q3 2019 in Review

JNBA Financial Advisors sold out of Karyopharm Therapeutics (KPTI) in Q3 2019, closing a stake of 27 shares — an estimated $2K sold.

JNBA Financial Advisors first reported a position in KPTI in Q2 2019 and held it in 1 quarter. The position peaked at $2K in Q2 2019. 106 funds tracked by Wall St. Rank hold KPTI as of Q3 2019.

  • JNBA Financial Advisors reported no remaining Karyopharm Therapeutics position as of Q3 2019 after selling out during the quarter.
  • JNBA Financial Advisors sold 27 Karyopharm Therapeutics shares in Q3 2019, an estimated $2K.
  • JNBA Financial Advisors first reported a position in Karyopharm Therapeutics in Q2 2019 and held it in 1 quarter.
  • JNBA Financial Advisors's Karyopharm Therapeutics position peaked at $2K in Q2 2019.
  • 106 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2019.

Based on JNBA Financial Advisors's 13F filing for Q3 2019, filed 1 Nov 2019.